Connect Biopharma Holdings Limited (CNTB): Price and Financial Metrics
GET POWR RATINGS... FREE!
CNTB Stock Price Chart Interactive Chart >
CNTB Price/Volume Stats
| Current price | $0.91 | 52-week high | $29.27 |
| Prev. close | $0.88 | 52-week low | $0.56 |
| Day low | $0.83 | Volume | 498,900 |
| Day high | $1.02 | Avg. volume | 281,060 |
| 50-day MA | $2.35 | Dividend yield | N/A |
| 200-day MA | $9.63 | Market Cap | 50.12M |
Connect Biopharma Holdings Limited (CNTB) Company Bio
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Latest CNTB News From Around the Web
Below are the latest news stories about Connect Biopharma Holdings Ltd that investors may wish to consider to help them evaluate CNTB as an investment opportunity.
Connect Biopharma (CNTB) presents at SVB Leerink 11th Annual Global Healthcare Conference - SlideshowNo summary available. |
Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare ConferenceSAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 4:20 pm ET. |
Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo —Analyses demonstrate that the benefits of CBP-201 to patients continue to increase as baseline disease severity increases — —Data and analyses support the potential for a highly competitive efficacy and safety profile for CBP-201 that includes a differentiated Q4W dosing schedule — SAN DIEGO, C |
Connect Biopharma''s Latest Dermatitis Drug Update Fails To Pump Up SharesNo summary available. |
Leerink Partners Thinks Connect Biopharma Holdings’ Stock is Going to RecoverIn a report released today, Thomas Smith from Leerink Partners maintained a Buy rating on Connect Biopharma Holdings (CNTB – Research Report), with a price target of $22.00. The company's shares closed last Wednesday at $5.00, close to its 52-week low of $4.10. According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.3% and a 21.4% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Prometheus Biosciences, and Eledon Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings. |
CNTB Price Returns
| 1-mo | -66.30% |
| 3-mo | N/A |
| 6-mo | -78.98% |
| 1-year | -94.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -82.33% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...